DMK Logo
DMK
DMK Pharmaceuticals Corp
$0.23
0.91%
Company Details
Name

DMK Pharmaceuticals Corp

Website

http://www.adamispharmaceuticals.com/

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

Categories

CEO

Dennis Carlo

Employees

17

Description

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a

Stock Quote
Market Cap

$2.34M

52 Week High

$0.23

PE Ratio

-0.04

52 Week Low

-

EPS

-$6.37

Shares Outstanding

10.10M

Dividend Yield

-

Dividend Per Share

-

Company Details
Name

DMK Pharmaceuticals Corp

Website

http://www.adamispharmaceuticals.com/

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

Categories

CEO

Dennis Carlo

Employees

17

Description

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a

Latest News
Related Stocks